Key strategic actions included the launch of CREXONT, entry into the GLP-1 market through a collaboration with Metsera, and expansion of the biosimilars pipeline. CREXONT, a treatment for ...

Regarding tariffs, Barclays estimates the financial impact of existing and potential duties on Sandoz at $25-$35 million in 2025, with an annualized impact of $35-$50 million. If the European Union ...

Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

SHANGHAI, China & JERSEY CITY, NJ, USA I March 28, 2025 I Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the ...

Bio-Thera and Dr. Reddy's partner for biosimilar commercialization in Southeast Asia, expanding access to affordable ...

At the same time, our strong in-house R&D capabilities have put Alvotech in a leading position among pure play biosimilar companies in terms of the market value of our product pipeline.

(Gedeon Richter), and the associated cash capital increase at the beginning of 2024, allowed Formycon to raise €82.84 million for the further development of its existing biosimilar pipeline. In return ...

Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 ... (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI ...